BAVARIAN NORDIC/S (OTCMKTS:BVNRY) is set to issue its quarterly earnings data before the market opens on Wednesday, May 22nd. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.
BVNRY stock opened at $6.64 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.84 and a current ratio of 6.15. BAVARIAN NORDIC/S has a 52 week low of $5.92 and a 52 week high of $10.78.
Separately, Zacks Investment Research lowered shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th.
About BAVARIAN NORDIC/S
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
Recommended Story: Should You Consider an Index Fund?
Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.